RxDoctor Payments Data

Gary McEwen, MD

Dermatology · Lee's Summit, MONPI 1477554657

Payments from drug & device makers

$6,583in general payments, 2019–2025

Across 323 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$631
  • Sun Pharmaceutical Industries Inc.$612
  • E.r. Squibb & Sons, L.L.C.$508
  • UCB, Inc.$428
  • Regeneron Healthcare Solutions, Inc.$392
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,33996%
  • Education$2444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,583 in reported general payments places this provider in the 65th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$515,812
Medicare patients
1,688
Services billed
9,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast39$218,559
TremfyaGuselkumab12$159,868
EnbrelEtanercept12$86,865
Cosentyx (2 Syringes)Secukinumab12$86,427
Dupixent SyringeDupilumab12$45,014
Clobetasol Propionate286$12,645
Ketoconazole551$8,401
Metronidazole131$5,677
Doxycycline Hyclate285$5,663
Betamethasone Dipropionate152$5,593
Fluorouracil75$4,673
Triamcinolone Acetonide395$4,185
Azelaic Acid23$2,879
Tacrolimus27$2,591
Imiquimod72$2,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$353$305,42451 claims
Johnson & JohnsonTremfya$631$159,86812 claims
NovartisCosentyx (2 Syringes)$298$86,42712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 263 dermatology providers in Missouri.

Other dermatology in Lee's Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →